Skip to main content
Fig. 4 | Arthritis Research & Therapy

Fig. 4

From: A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis

Fig. 4

Change from baseline in IL-6 and sIL-6R levels during the 52W treatment period — safety population: a) mean change in IL-6 levels (ng/L) over time and b) mean change in sIL-6R levels (ng/mL) over time. IL-6, interleukin-6; PBO, placebo; Q2W, every 2 weeks; SAR150/200, sarilumab 150/200 mg; SE, standard error; sIL-6R, soluble IL-6 receptor; W, week

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us